# A Study to Evaluate Raptiva in Combination With Topical Psoriasis Therapies

> **NCT00096980** · PHASE4 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 300 (—)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Raptiva (efalizumab)

## Key facts

- **NCT ID:** NCT00096980
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-02
- **Primary completion:** —
- **Final completion:** 2004-05
- **Target enrollment:** 300 (—)
- **Last updated:** 2013-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00096980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00096980, "A Study to Evaluate Raptiva in Combination With Topical Psoriasis Therapies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00096980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*